Company profile:

Natco pharma limited is a technology driven company specialized in the manufacture of Pharmaceuticals involving Novel drug delivery systems, Active pharmaceutical ingredients and also engaged in custom synthesis and contract manufacturing activities. V.C.Nannapaneni (M.Pharm, Andhra University, India, MS (Administration) Long Island University, USA) founded the company in the year 1982 after his 15 year employment in the United States.  The current turnover of the company is about 30 million US$. The company is in the manufacture of anti-migraine drugs, proton pump inhibitors, and anti-depressants to name a few.

The company has excellent infrastructure in terms of technical facilities, research excellence and qualified personnel. The company has spent over 20 million US$ on its state of the art research division (Natco Research Center) committed to develop cost effective and environmentally friendly technologies. The corporate R&D has over 20 Ph.D’s and over 150 postgraduates covering various disciplines of Pharmaceutical sciences and Drug development. The R&D center has filed several patents in the fields of Process chemistry, Novel formulations and Drug delivery systems.

The company’s manufacturing divisions (API/Formulations) follow International cGMP norms and one of the divisions has got TGA (Australia) accreditation .The facilities are poised to receive US FDA and MCA, U.K approvals in the current year. One of the key activities of the formulation division is contract manufacturing catering to the needs of a good number of Multinationals in India.

With a mission to make the extra-ordinarily expensive anti cancer drugs affordable and to reach all sections of Indian society, the Company has recently included anti-neoplastic segment in its portfolio. ”VEENAT” is the first successful and fruitful product that emerged out during these efforts of the company. The brand name is derived based on the colloquial interpretation in an Indian language meaning “ Music of Life”. “VEENAT” capsule is colored green signaling promise of life and vitality.

The sustained efforts of the company to optimize the manufacturing process of VEENAT (Covering both the API and the formulated capsule) resulted in substantially lower production costs thus enabling the company to successfully adopt a pricing structure that can comfort thousands of CML patients in India. The current pricing structure of US$3/Capsule is expected to reduce further considerably during the next year. The company has firmed up plans to make the drug available free of cost to a section of CML patients. This is undertaken as a part of company’s social service and welfare activity measures through NATCO TRUST.